Table 2.
Neurodevelopmental outcomes, respiratory outcomes and long‐term healthy survival of children participating in follow‐up
| Complete case analysis (N = 56) | |||
|---|---|---|---|
| Assessed for neurodevelopment and health outcomes | Amnioinfusion (n = 10) | No intervention (n = 4) | RR (95% CI) |
| No neurodevelopmental delay a | 8/28 | 2/28 | 4.00 (0.93–17.19) |
| Percentage of all assessed surviving infants b | 80% | 50% | |
| Percentage of all included participants c | 28.6% | 7.1% | |
| Percentage of all participants with known outcome d | 28.6% | 8% | |
| Bayley/WPSSI mild delay (−1SD) | 8 (28.6%) | 2 (7.1%) | 4.00 (0.93–17.19) |
| Bayley/WPSSI severe delay (−2SD) | 0 (0%) | 0 (0%) | — |
| No respiratory problems e | 6/28 | 3/28 | 2.00 (0.55–7.22) |
| Percentage of all assessed surviving infants b | 60% | 75% | |
| Percentage of all included participants c | 21.4% | 10.7% | |
| Percentage of all participants with known outcome d | 21.4% | 12% | |
| Respiratory symptoms disturbing daily activities f | 1 (3.6%) | 0 (0%) | — |
| Anti‐asthmatic medication g | 2 (7.1%) | 1 (3.6%) | 2.00 (0.19–20.82) |
| Visits to a paediatric pulmonologist h | 1 (3.6%) | 1 (3.6%) | 1.00 (0.7–15.21) |
| Composite healthy survivor i | 5/28 | 2/28 | 2.50 (0.53–11.83) |
| Percentage of all assessed surviving infants b | 50% | 50% | |
| Percentage of all included participants c | 17.9% | 7.1% | |
| Percentage of all participants with known outcome d | 17.9% | 8% | |
Data presented as n (%).
Neurodevelopmental delay defined as: scores for a mild neurodevelopmental delay with a cut off of −1 SD in any of the 2 indexes of the Bayley‐III‐NL or in any of the 3 scales of the WPPSI‐III‐NL.
Percentage of all infants that were assessed for follow‐up, n = 10 in the amnioinfusion group, n = 4 in the no intervention group.
Percentage of all included participants, n = 28 in the amnioinfusion group, n = 28 in the no intervention group.
Percentage of participants with a known outcome, n = 28 in the amnioinfusion group, n = 25 in the no intervention group (three infants lost to follow‐up).
Respiratory problems defined as: at least once a week respiratory symptoms interfering with daily activities (i.e. not able to attend school or not able to play) in the past four weeks, or visits to a paediatric pulmonologist from birth until current age, or use of anti‐asthmatic medication for respiratory symptoms at least ≥1 time/week.
Respiratory symptoms interfering with daily activities (i.e. not able to attend school or not able to play) at least once a week over the past four weeks.
Use of anti‐asthmatic medication at least ≥1 time/week from birth until current age.
Visits to a pulmonologist from birth until current age.
Healthy survivor defined as: no neurodevelopmental delay or no respiratory problems.